VYNE THERAPEUTICS
VYNE Therapeutics is a clinical late-stage biopharmaceutical company that focuses on the development and commercialization of serlopitant for the treatment of pruritus (itch) associated with dermatologic conditions such as atopic dermatitis, psoriasis, and prurigo nodularis.
VYNE THERAPEUTICS
Industry:
Health Care Pharmaceutical Therapeutics
Founded:
2003-01-01
Address:
Menlo Park, California, United States
Country:
United States
Website Url:
http://www.vynetherapeutics.com
Total Employee:
11+
Status:
Active
Contact:
(650)486-1416
Email Addresses:
[email protected]
Total Funding:
297.84 M USD
Technology used in webpage:
Euro Cloudflare Hosting Getty Images
Similar Organizations
Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Nivalis Therapeutics
Nivalis Therapeutics is a clinical-stage pharmaceutical company developing a novel class of disease modifying therapies.
Recro Pharma
Recro Pharma is a pharmaceutical company developing non-opioid therapeutics for the treatment of pain.
Southern Scripts
Southern Scripts is the complexities of navigating through the Pharmacy Benefit Manager world by giving the employer group complete freedom.
TCR2
TCR2 is a discovery stage pharmaceutical company that developed a unique proprietary TRuCโข platform.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2020-03-09 | Foamix | Foamix acquired by VYNE Therapeutics | N/A |
Investors List
Palo Alto Investors
Palo Alto Investors investment in Post-IPO Equity - VYNE Therapeutics
Acorn Bioventures
Acorn Bioventures investment in Post-IPO Equity - VYNE Therapeutics
Soleus Capital
Soleus Capital investment in Post-IPO Equity - VYNE Therapeutics
Eventide
Eventide investment in Post-IPO Equity - VYNE Therapeutics
Access Biotechnology
Access Biotechnology investment in Post-IPO Equity - VYNE Therapeutics
Parkman Healthcare Partners
Parkman Healthcare Partners investment in Post-IPO Equity - VYNE Therapeutics
Cormorant Asset Management
Cormorant Asset Management investment in Post-IPO Equity - VYNE Therapeutics
Surveyor Capital
Surveyor Capital investment in Post-IPO Equity - VYNE Therapeutics
Remeditex Ventures
Remeditex Ventures investment in Series C - VYNE Therapeutics
Presidio Partners
Presidio Partners investment in Series C - VYNE Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2024-07-09 | VYNE Therapeutics Announces Appointment of Subhashis Banerjee, M.D. as Senior Vice President of Clinical Development |
Official Site Inspections
http://www.vynetherapeutics.com Semrush global rank: 4.81 M Semrush visits lastest month: 1.84 K
- Host name: 141.193.213.11
- IP address: 141.193.213.11
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "VYNE Therapeutics"
About Us โ VYNE Therapeutics
Working to solve difficult therapeutic challenges. VYNE Therapeutics ® is working to solve some of todayโs most difficult therapeutic challenges. With every problem we take on, our โฆSee details»
Who We Are โ VYNE Therapeutics
The core of VYNE Therapeutics ® is a hand-picked team of pharmaceutical industry professionals from all over the world who have come together to push past the conventional thinking โฆSee details»
VYNE Therapeutics โ Rooted in Innovation
Rooted in Innovation. VYNE Therapeutics ® is working to solve some of todayโs most difficult therapeutic challenges. With every problem we take on, our approach is the same: question โฆSee details»
VYNE Therapeutics Inc. | LinkedIn
VYNE Therapeutics is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immunological (I&I) conditions with โฆSee details»
VYNE Therapeutics Inc. (VYNE) Company Profile & Facts - Yahoo โฆ
See the company profile for VYNE Therapeutics Inc. (VYNE) including business summary, industry/sector information, number of employees, business summary, corporate governance, โฆSee details»
VYNE Therapeutics - Israeli Startup | Startup Nation Finder
Dec 7, 2022 VYNE Therapeutics is a biopharmaceutical company focused on developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions.See details»
VYNE Therapeutics Inc. (VYNE) - Yahoo Finance Canada
See the company profile for VYNE Therapeutics Inc. (VYNE) including business summary, industry/sector information, number of employees, business summary, corporate governance, โฆSee details»
VYNE Therapeutics Inc. (VYNE) Company Profile & Overview
Jan 25, 2018 685 Route 202/206 N, Suite 301 Bridgewater, New Jersey 08807 United StatesSee details»
VYNE Therapeutics - VentureRadar
Similar Companies: Sun BioPharma USA Privately Held Sun BioPharma is developing small-molecule pharmaceuticals consisting of novel polyamine analogues and metal chelators, and โฆSee details»
VYNE Therapeutics - Overview, News & Similar companies
VYNE Therapeutics Announces Oral Presentations for VYN201 at the 2024 Society for Investigative Dermatology (SID) Annual Meeting BRIDGEWATER, N.J., May 01, 2024 โฆSee details»
VYNE Therapeutics Announces the Appointment of Patrick G.
BRIDGEWATER, N.J., Sept. 14, 2020 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (โVYNEโ or the โCompanyโ) today announced that the Board of Directors of the โฆSee details»
Our Mission โ VYNE Therapeutics
VYNE Therapeutics ® is working to solve some of todayโs most difficult therapeutic challenges. With every problem we take on, our approach is the same: question traditional assumptions โฆSee details»
VYNE Therapeutics Inc. Overview | SignalHire Company Profile
VYNE Therapeuticsโ mission is to improve the lives of patients by developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions.See details»
VYNE Therapeutics - PitchBook
VYNE Therapeutics General Information Description. VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated โฆSee details»
VYNE Therapeutics Completes Enrollment in Phase 2b Trial โฆ
5 days ago VYNE Therapeutics Inc. Once-daily VYN201 gel being evaluated in subjects with nonsegmental vitiligo. Top-line data from the 24-week double-blind portion of the trial expected โฆSee details»
VYNE Completes Phase 2b Enrollment for Vitiligo Gel
5 days ago VYNE Therapeutics announced today the completion of enrollment in a phase 2b trial of repibresib (VYN201) gel for nonsegmental vitiligo. This milestone marks significant โฆSee details»
VYNE Therapeutics, Inc. (VYNE Therapeutics, Inc.) - ่ฏ็ฉ็ฎก็บฟ_ไธๅฉ_ โฆ
For more information about VYNE Therapeutics Inc. or its product candidates, visit www.vynetherapeutics.com. VYNE may use its website to comply with its disclosure โฆSee details»
VYNE Therapeutics Completes Enrollment in Phase 2b Trial for
5 days ago VYNE Therapeutics has completed enrollment for its Phase 2b trial of VYN201 gel, now named repibresib, for treating nonsegmental vitiligo, with top-line results expected in mid โฆSee details»
VYNE Therapeutics Inc. (VYNE) Stock Price, News, Quote & History ...
Find the latest VYNE Therapeutics Inc. (VYNE) stock quote, history, news and other vital information to help you with your stock trading and investing.See details»
Careers โ VYNE Therapeutics
If you are ready to become a member of the VYNE Therapeutics team, click here to send us your resume and/or cover letter. VYNE Therapeutics is an equal opportunity employer. Employment โฆSee details»